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Abstract
Background: The use of Salmonella to deliver heterologous antigens from DNA vaccines is a well-accepted extension of the
success of oral Salmonella vaccines in animal models. Attenuated S. typhimurium and S. typhi strains are safe and efficacious,
and their use to deliver DNA vaccines combines the advantages of both vaccine approaches, while complementing the
limitations of each technology. An important aspect of the basic biology of the Salmonella/DNA vaccine platform is the
relative contributions of prokaryotic and eukaryotic expression in production of the vaccine antigen. Gene expression in
DNA vaccines is commonly under the control of the eukaryotic cytomegalovirus (CMV) promoter. The aim of this study was
to identify and disable putative bacterial promoters within the CMV promoter and evaluate the immunogenicity of the
resulting DNA vaccine delivered orally by S. typhimurium.
Methodology/Principal Findings: The results reported here clearly demonstrate the presence of bacterial promoters within
the CMV promoter. These promoters have homology to the bacterial consensus sequence and functional activity. To disable
prokaryotic expression from the CMV promoter a series of genetic manipulations were performed to remove the two major
bacterial promoters and add a bacteria transcription terminator downstream of the CMV promoter. S. typhimurium was used
to immunise BALB/c mice orally with a DNA vaccine encoding the C-fragment of tetanus toxin (TT) under control of the
original or the modified CMV promoter. Although both promoters functioned equally well in eukaryotic cells, as indicated
by equivalent immune responses following intramuscular delivery, only the original CMV promoter was able to induce an
anti-TT specific response following oral delivery by S. typhimurium.
Conclusions: These findings suggest that prokaryotic expression of the antigen and co-delivery of this protein by
Salmonella are at least partially responsible for the successful oral delivery of C-fragment DNA vaccines containing the CMV
promoter by S. typhimurium.
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Introduction
Oral delivery of DNA vaccines by Salmonella was first reported in
1997 [1]. In the decade that followed, Salmonella has been used to
deliver DNA vaccines targeting a variety of pathogens, and for
cancer immunotherapy (for reviews see [2–5]). The use of Salmonella
to deliver heterologous antigens is a natural extension of the success
of oral Salmonella vaccines. Attenuated S. typhimurium and S. typhi
strains are safe and efficacious [6] and their use to deliver DNA
vaccines combines the advantages of both vaccine approaches,
while complementing the limitations of each technology.
Previous studies involving DNA delivery by Salmonella have
commonly used plasmids with gene expression under the control
of the cytomegalovirus (CMV) promoter. There have been
contrasting reports on the existence of bacterial promoters within
the CMV promoter. Studies using green fluorescent protein (GFP)
[7,8] and beta galactosidase (b-gal) [1,9] have concluded that gene
expression occurred in eukaryotic cells but not in Salmonella,
however, expression was not examined for resultant immunoge-
nicity. In contrast, Goussard et al. [10] found expression of lacZ
and GFP in S. typhimurium and E. coli from the CMV promoter.
Sequences within the CMV promoter used by bacteria could
confound attempts to optimise antigen expression as the resulting
immune response might comprise contributions from both
eukaryotic and prokaryotic expression, with the extent of each
contribution unknown. There have been no published reports
examining whether Salmonella can be used for the oral delivery of a
DNA vaccine in the absence of bacterial expression. The aim of
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e6062this study was to identify the location of putative bacterial
promoters within the CMV promoter, and to construct a DNA
vaccine with the bacterial expression component removed, to
determine if prokaryotic expression contributes to the immunoge-
nicity of DNA vaccines orally delivered by S. typhimurium.
Methods
Bacterial strains and plasmids
S. typhimurium strain BRD509 is an aroA/aroD mutant of SL1344
and was the gift of Prof. G. Dougan, Imperial College, London,
UK. All DNA manipulations were carried out in E. coli (strain
JM109 or DH5a). Bacterial strains were routinely cultured in Luria
Bertani (LB) or LB agar and when required, were supplemented
with 100 mgml
21 ampicillin and 25 mgml
21 streptomycin. The
plasmid pcDNA3/Cfrag, which contains the codon optimised C-
fragment of tetanus toxoid under the controlof the CMV promoter,
was the gift of L. Sait, Department of Microbiology and
Immunology, University of Melbourne, Australia. The plasmids
pAT153 [11], pTETtac4 containing a C-fragment expression
cassette [12], pCRH2.1-TOPO (Invitrogen, Mount Waverley,
Australia) and pMu2385 [13] were used in this study.
Western blot analysis
Whole-cell protein samples were prepared from overnight (O/
N) bacterial cultures. Aliquots (300–500 ml) of bacterial culture
were centrifuged at 15,000 g for five minutes. The pellet was
resuspended in 100 mlo f5 6 sample loading dye (1 M Tris
pH 6.8, 10% SDS, glycerol and 10% (v/v) mercaptoethanol) and
boiled prior to loading. Protein samples were separated by 10%
SDS-PAGE and transferred to nitrocellulose in blotting buffer
(1.44% (w/v) glycine, 0.3% (w/v) Tris and 20% (v/v) methanol)
using a Bio-Rad western blotting apparatus at 100 volts for one
hour. The nitrocellulose was blocked for one hour at room
temperature with 5% skim milk in phosphate buffered saline
(PBS), incubated with primary antibody diluted 1/200–1/1000 in
PAT (PBS containing 0.05% Tween20 and 0.5% skim milk
powder) O/N at room temperature. Following incubation with an
anti-mouse Ig affinity isolated horse radish peroxidase conjugated
secondary antibody (Chemicon, Temecula, CA, USA) diluted 1/
1000 in PAT at room temperature for two hours, proteins were
visualised by TMB Membrane Peroxidase Substrate (KPL, MD,
USA). The primary antibody was an anti-tetanus toxin antibody
generated by subcutaneously immunising five BALB/c mice with
100 ml Tetanus Toxin (CSL Limited, Parkville, VIC, Australia) on
day 0 and 49. The sera was collected and pooled on day 56.
RNA extraction
Total cellular RNA was extracted from early-log phase bacterial
cultures using the Qiagen RNeasy mini kit (QIAGEN, Doncaster,
VIC, Australia). RNA concentration and purity was determined
by spectrophometry.
Primer labelling with
32P
An oligonucleotide (59-AACTCCCATTGACGTCAATGGG-
39) was radiolabelled at the 59 end in a 20 ml reaction containing
70 mM Tris pH 7.6, 10 mM MgCl2, 5 mM dithiothreitol (DTT),
1 ml[c-
32P]ATP and one unit of T4 polynucleotide kinase.
Incubation was carried out at 37uC for 30 minutes, followed by
heat inactivation at 70uC for 15 minutes.
Primer extension
Hybridisation of a [c-
32P]ATP-labelled oligonucleotide to RNA,
followed by extension of the primer using AMV reverse
transcriptase (Promega, Sydney, NSW, Australia), was carried
out according to the method of Hudson and Davidson [14].
Briefly, the oligonucleotide (50,000–100,000 CPM) was hybridised
to 150 mg/ml of RNA in the presence of 56 mM Tris pH 7.5,
20 mM MgCl2 and 31.8 mM DTT in a total volume of 50 ml, by
heating to 75uC for two minutes and slow cooling to room
temperature. Following ethanol precipitation, the pellet was
resuspended in 10 ml of 50 mM Tris pH 8.8, 10 mM MgCl2,
140 mM KCl, 10 mM DTT, 4 mM tetrasodium pyrophosphate
and 100 mM each of the four dNTPs. The primer was extended
with five units of reverse transcriptase for two hours at 42uC. After
ethanol precipitation, the samples were resuspended in formamide
dye mix, denatured and loaded onto a 6% sequencing gel.
b-galactosidase assay
Plasmid pMu2385 is a single copy plasmid which carriers a
promoter-less lacZ structural gene with its own translational start
signals [13]. CMV promoter regions were excised from the
corresponding pcDNA3/Cfrag constructs with Bgl II and Hind III
and ligated into pMu2385 digested with BamH I and Hind III.
Cultures of E. coli (DH5a) containing the b-galactosidase vector
were grown in LB at 37uC shaking to mid-exponential phase
(OD600 of 0.4–0.6) and b-galactosidase activity was assayed as
described by Miller [15]. Assays were performed in duplicate on at
least three separate occasions.
Ethics statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
welfare bodies, and all animal work was approved by the
University of Melbourne animal ethics committee.
Intramuscular immunisation
Female 6–8 week old BALB/c mice were obtained from The
University of Melbourne, Department of Microbiology and
Immunology animal facility (Parkville, Victoria, Australia).
Endotoxin free DNA vaccines, obtained using EndoFreeH Plasmid
kits (QIAGEN, Doncaster, VIC, Australia), were diluted to 1 mg/
ml in 0.9% sterile saline. 50 mg of DNA was injected intramuscu-
larly in both hind legs of the mice (100 mg total dose).
Oral immunisation with S. typhimurium
Mice were orally immunised under anaesthesia (Penthrane) via
a 4 cm gastric lavage needle with approximately 10
10 bacteria in
PBS (200 ml/mouse) as determined by retrospective viable count.
Bacteria were grown static in LB containing antibiotics at 37uC for
24 h. Thirty minutes prior to immunisation mice were orally
administered 100 ml of 10% (w/v) sodium bicarbonate to
neutralise stomach acidity.
Measurement of antibody response by enzyme-linked
immunosorbent assay (ELISA)
On designated days mice were bled from the tail vein and the titre
of antibody present for S. typhimurium LPS and TT was determined by
end-point ELISA as previously described [16]. Total Ig was detected
by the addition of 1/1000 anti-mouse Ig Horseradish peroxidase
conjugate (Chemicon, Temecula, CA, USA). Serum antibody titres
were designated as the reciprocal of the dilution of antibody that gave
an OD492 value five times the background of the assay.
Statistical analysis
The non-parametric Mann Whitney test was used to compare
groups of data. A probability (P) value of less than 0.05 indicated
Salmonella DNA Delivery
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groups which contained values below the point of detection of the
assay, an arbitrary value one below the limit of the assay was
assigned.
Results
Expression of C-fragment in S. typhimurium BRD509
To determine if C-fragment protein was produced from the
DNA vaccine plasmids, total protein from overnight cultures of S.
typhimurium BRD509 was analysed by western blot. Two protein
species were detected (figure 1). A non-specific band at ,55 kDa
was present in all samples, and the C-fragment protein at
,47.5 kDa was detected for BRD509 containing pTETtac4 and
pcDNA3/Cfrag but not for pcDNA3 or BRD509 alone. These
results indicate that bacterial promoter activity, either within, or
upstream of, the CMV promoter caused read-through transcrip-
tion into the C-fragment gene resulting in bacterial expression.
Identification and location of bacterial promoter
sequences within the CMV promoter
The transcription initiation sites of the bacterial promoter
sequences were identified by primer extension analysis using RNA
extracted from BRD509 (pcDNA3/Cfrag) and BRD509. Two
strong primary bacterial transcription initiation sites situated
within the CMV promoter and multiple minor promoters were
identified (figure 2). The first of these (promoter one, P1) is located
428 base pairs (bp) upstream of the AP1 region of the CMV
promoter and the second promoter (promoter two, P2) is 292 bp
upstream of AP1. Both bacterial promoters are located upstream
of the CMV promoter regulatory elements and the C-fragment
start codon (figure 3a). Comparison of the 235 and 210 regions of
the promoters with the bacterial consensus sequence revealed a
perfect alignment for the P1 promoter at the 235 position and
only two nucleotide changes in the 210 sequence (figure 3b). In
addition, the P1 sequence displayed optimal spacing of 17 bp
between the 235 and 210 sequence elements. Promoter two
contained a near perfect 235 region and an optimal spacer of
17 bp. Although the 210 region is less conserved, there is a TGT
motif one base upstream of the 210 region which is known to
enhance transcription [17,18].
Determination of bacterial promoter activity following
removal of the two primary bacterial promoters
C-fragment plasmids were constructed using PCR and restric-
tion enzyme digests with either P1 (pcDNA3/Cfrag-P1), P2
(pcDNA3/Cfrag-P2) or both bacterial promoter regions removed
(pcDNA3/Cfrag-P1/2). To determine if bacterial C-fragment
expression had been eliminated, total protein from overnight
cultures of S. typhimurium BRD509 was analysed by western blot.
C-fragment protein expression was detected for BRD509 contain-
ing pcDNA3/Cfrag, pcDNA3/Cfrag-P1, pcDNA3/Cfrag-P2 and
pcDNA3/Cfrag-P1/2 but not for BRD509 alone (figure 4a). The
degree of protein expression for the three modified constructs
appeared to be similar to pcDNA3/Cfrag which contains the
unmodified CMV promoter.
To determine if differences between the constructs were masked
by the high copy number of pcDNA3, CMV-lacZ transcriptional
fusions of the pCMV, pCMV-P1, pCMV-P2 and pCMV-P1/2
promoter regions were constructed to quantify bacterial promoter
activity. The single promoter mutations (pCMV-P1 and pCMV-
P2) resulted in an approximately 2.6 fold reduction in b-
galactosidase activity compared with the unmodified CMV
promoter, which produced 76 units of b-galactosidase activity
(figure 4b). There was no further reduction in promoter activity
when both primary bacterial promoters were mutated (pCMV-
P1/2). Although removal of the two primary bacterial promoter
sequences resulted in a reduction in promoter activity, it did not
Figure 1. Expression of C-fragment in attenuated S. typhimur-
ium BRD509. Western immunoblots showing expression of C-
fragment encoded on various plasmids. Cell lysates of (1) BRD509
(pTETtac4), (2) BRD509, (3) BRD509 (pcDNA3/Cfrag), and (4) BRD509
(pcDNA3) probed with polyclonal anti-tetanus toxin antiserum. C-
fragment expression is indicated by the arrow.
doi:10.1371/journal.pone.0006062.g001
Figure 2. Determination of S. typhimurium transcription initia-
tion sites within the CMV promoter by primer extension. A 22-
base oligonucleotide primer labelled with P
32 was hybridised to RNA
from BRD509 (lane 2) and BRD509 (pcDNA3/Cfrag) (lane 3) and
extended with reverse transcriptase. The products, along with a
sequencing ladder generated from pcDNA3/Cfrag (lane 1), were run
on a denaturing gel. The primary bacterial transcription initiation sites
are indicated with arrows.
doi:10.1371/journal.pone.0006062.g002
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cultures this could be due to the additional minor bacterial
promoters identified within the CMV promoter (figure 2).
Additionally, studies have also identified different bacterial
promoters within the CMV promoter which are utilised by E.
coli [25] and these are likely to account for the results of the b-
galactosidase quantification assay which was done in E. coli.
Determination of bacterial promoter activity following
insertion of a bacterial transcription terminator
As it was impractical to remove or mutate all the minor
bacterial promoters, the trpA bacterial transcription terminator
[19] was inserted into pcDNA3/Cfrag and pcDNA3/Cfrag-P1/2
at the junction between the 39 end of the CMV promoter and the
59 start of the C-fragment gene. These constructs were designated
pcDNA3/Cfrag-T and pcDNA3/Cfrag-P1/2-T. To determine if
bacterial protein expression had been eliminated following
insertion of the trpA terminator total protein from overnight
cultures of S. typhimurium BRD509 was analysed by western blot.
Strong C-fragment protein expression was detected from
pcDNA3/Cfrag. In contrast, bacterial expression from
pcDNA3/Cfrag-T and pcDNA3/Cfrag-P1/2-T was negligible
(figure 5a).
To quantify bacterial promoter activity the pCMV, pCMV-P1/
2-T and pCMV-T regions were ligated into pMu2385. The
inclusion of the bacterial terminator resulted in a 17-fold reduction
in b-galactosidase activity from 76 units for the unmodified CMV
promoter to 4.5 units for both pCMV-P1/2-T and pCMV-T.
Although substantially reduced, the b-galactosidase activity was
still greater than the 0.625 units of b-galactosidase activity detected
for the empty vector (figure 5b).
Humoral immune response following intramuscular
immunisation of the modified CMV promoter constructs
Groups of five BALB/c mice were intramuscularly injected with
pcDNA3, pcDNA3/Cfrag, pcDNA3/Cfrag-T and pcDNA3/
Cfrag-P1/2-T DNA on days 0 and 7 to determine in vivo
functionality and ability to induce an anti-TT antibody response.
Four of the five mice immunised with pcDNA3/Cfrag, pcDNA3/
Cfrag-T and pcDNA3/Cfrag-P1/2-T responded to the DNA
vaccines at day 56 with average titers of 118, 121 and 175
respectively (figure 6). One mouse immunised with pcDNA3 also
responded with a titer of 65. There was no significant difference
between titres of mice immunised with pcDNA3/Cfrag,
pcDNA3/Cfrag-T and pcDNA3-P1/2-T and all groups were
significantly higher than the negative control group which received
pcDNA3 (P,0.05).
Humoral immune response following oral delivery of
modified CMV promoter constructs by S. typhimurium
BRD509
Prior research has shown that pAT153 is stable in vitro and in vivo
and is the optimal plasmid for oral delivery by S. typhimurium [16].
Therefore, the C-fragment vaccine cassette from pcDNA3/Cfrag-
P1/2-T and pcDNA3/Cfrag-T was cloned into pAT153 to
generate pAT153/Cfrag-P1/2T and pAT153/Cfrag-T. Groups
of five BALB/c mice were orally immunised with S. typhimurium
BRD509 containing the plasmids pAT153, pAT153/Cfrag,
Figure 3. Location of S. typhimurium promoter sequences within the CMV promoter. (A) DNA sequence of pcDNA3/Cfrag from the start of
the CMV promoter highlighting the location of the two primary bacterial promoters (blue), the regulatory regions of the CMV promoter (red) and the
start codon of the C-fragment gene (underlined). (B) Alignment of the 235 and 210 promoter regions of the two primary S. typhimurium promoters
with the bacterial promoter consensus sequence. The TGT enhancer region located within promoter 2 is shown in bold.
doi:10.1371/journal.pone.0006062.g003
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nised on days 0 and 35 and their serum antibody response (total Ig)
specific for S. typhimurium LPS and tetanus toxoid (TT) was
determined by ELISA at days 28 and 56.
Anti-LPS total Ig was detected in the sera of all immunised mice
(figure 7a). The pattern and titre of the antibody response was
similar in all groups of mice. There was no significant difference in
LPS responses between the groups, nor was there a difference
between days 28 and 56, indicating all groups received the same
dose of Salmonella. At day 56, the anti-TT antibody titres for
pAT153/Cfrag were significantly higher than both pAT153/
Cfrag-T and pAT153/Cfrag-P1/2-T with average titres of 1652,
181 and 93, respectively. There was no difference between
pAT153/Cfrag-T and pAT153/Cfrag-P1/2-T and the negative
control group who received pAT153 alone (figure 7b).
Discussion
DNA vaccines have undergone many revisions and improve-
ments to reduce the required dosing, increase potency, and
ultimately reach commercialisation [20]. At the heart of this
process has been an ongoing research effort to better understand
the basic biology of DNA vaccines. The oral delivery of DNA
vaccines by Salmonella requires further optimisation if it is to be
commercialised. An important aspect of the basic biology of the
Salmonella/DNA vaccine platform is the relative contributions of
prokaryotic and eukaryotic expression in production of the vaccine
antigen. We examined whether an immune response can be
induced to a DNA vaccine delivered by Salmonella in the absence of
bacterial antigen expression. Therefore, the aim of this study was
to identify and disable putative bacterial promoters within the
CMV promoter and evaluate the immunogenicity of the resulting
DNA vaccine delivered orally by S. typhimurium.
Substantial amounts of C-fragment protein were detected in
cultures of S. typhimurium containing pcDNA3/Cfrag, a DNA
vaccine construct under the control of the CMV promoter. This
confirms the presence of bacterial promoters within the CMV
promoter sequence. Furthermore, quantification of bacterial
expression from the CMV promoter in an E. coli b-galactosidase
assay indicates that the amount of recombinant protein produced
by E. coli from the CMV promoter is similar to that reported for
other bacterial promoters [21,22]. Our results are consistent with
the study by Goussard et al. [10] who detected expression of GFP
and lacZ from the CMV promoter in S. typhimurium SL7207 and E.
coli. Interestingly, they found reporter gene expression to be higher
in the stationary phase of bacterial growth than the exponential
growth phase [10].
Primer extension analysis identified two primary and numerous
minor transcription initiation sites within the CMV promoter
which are utilised by S. typhimurium. The strong activity of the
primary bacterial promoters, P1 and P2, are most likely a
consequence of their homology to the bacterial promoter
consensus sequence [23]. Of the 12 positions in the consensus
sequence, most mRNA promoters match from seven to nine bases
[24]. The P1 and P2 promoters contain 10 and eight matching
bases respectively. Studies by Lewin et al. [25] using the rapid
amplification of 59 complementary DNA ends (59RACE) method
and plasmids containing the lux gene from Vibrio harveyi, have
Figure 4. Bacterial promoter activity of the original and mutated CMV promoter. (A) Western immunoblots showing expression of C-
fragment from S. typhimurium BRD509 containing pcDNA3/Cfrag (CMV), pcDNA3/Cfrag-P1 (P1), pcDNA3/Cfrag-P2 (P2), or pcDNA3/Cfrag-P1/2 (P1/2).
Purified C-fragment (pos) and BRD509 alone (neg) were included as controls. (B) To quantify promoter activity, the unmodified pCMV (CMV), pCMV-
P1 (P1), pCMV-P2 (P2) and pCMV-P1/2 (P1/2) were cloned into the b-galactosidase vector and promoter activity expressed as units of b-galactosidase
activity. Activity of the empty vector (neg) is included as a negative control.
doi:10.1371/journal.pone.0006062.g004
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utilised by E. coli. These promoters showed homology to the
bacterial 210 and 235 consensus sequences and resulted in strong
expression of a bacterial cytotoxin. Interestingly, the promoters
identified by Lewin et al.i nE. coli were situated in the later part of
the CMV promoter, in contrast to the location of the promoters
utilised by S. typhimurium which were mapped to early in the CMV
promoter region. This suggests there are multiple regions in the
Figure 6. Tetanus toxoid specific serum antibody response following intramuscular DNA immunisation. Groups of five BALB/c mice
were intramuscularly immunised with pcDNA3/Cfrag, pcDNA3/Cfrag-T, pcDNA3/Cfrag-P1/2-T or pcDNA3 on days 0 and 7. The tetanus toxin (TT)
specific serum total Ig antibody titres were determined by endpoint ELISA. Each symbol represents a titre from an individual mouse. The broken line
indicates the limit of the assay (1/50). *=significantly different from the pcDNA3 group (P,0.05).
doi:10.1371/journal.pone.0006062.g006
Figure 5. Bacterial promoter activity following insertion of the trpA bacterial transcription terminator. (A) Western immunoblots
showing expression of C-fragment from S. typhimurium BRD509 containing pcDNA3/Cfrag (CMV), pcDNA3/Cfrag-T (T) or pcDNA3/Cfrag-P1/2-T (P1/
2T). Purified C-fragment (pos) and BRD509 alone (neg) were included as controls. (B) To quantify promoter activity, the unmodified pCMV (CMV),
pCMV-T (T) and pCMV-P1/2-T (P1/2T) were cloned into the b-galactosidase vector and promoter activity expressed as units of b-galactosidase activity.
Activity of the empty vector (neg) is included as a negative control.
doi:10.1371/journal.pone.0006062.g005
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that different bacterial species may preferentially utilise specific
promoters.
There are very few reports addressing the relative contribution
of prokaryotic and eukaryotic expression to the target-specific
immune response. DNA vaccines with prokaryotic promoters are
ineffective when delivered by S. typhimurium, which indirectly
suggests that immune responses can be attributed to the use of
eukaryotic promoters [1,7,9]. Additionally, S. typhimurium studies
comparing the expression of GFP constructs with and without
introns, also support transcription of the target protein by
eukaryotic cells [8]. While these reporter gene studies support
the efficacy of eukaryotic transcription, they do not preclude a
contribution from prokaryotic expression when the CMV
Figure 7. S. typhimurium LPS and tetanus toxoid specific serum Ig antibody responses. Groups of five BALB/c mice were orally immunised
on day 0 and 35 with attenuated S. typhimurium BRD509 containing the plasmids pAT153/Cfrag, pAT153/Cfrag-T, pAT153/Cfrag-P1/2-T or pAT153.
Serum samples were collected on days 28 and 56. The amount of (A) S. typhimurium LPS-specific and (B) tetanus toxoid (TT)-specific total serum Ig
was determined by endpoint ELISA. Each symbol represents a titre from an individual mouse. The broken line indicates the limit of the assay (1/50).
*=significantly different from pAT153/Cfrag (P,0.05).
doi:10.1371/journal.pone.0006062.g007
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shown expression of C-fragment protein from the CMV promoter
in lysates of S. typhi vaccine strain CVD915 [26] and attenuated
Shigella flexneri 2a vaccine strain CVD1204 [27] under both aerobic
and non-aerobic conditions. Under aerobic conditions in lysates of
S. typhi CVD915 the level of prokaryotic expression of C-fragment
from the DNA vector was similar to that of the corresponding
protein vector as determined by western blot [26]. Despite this,
both reports argued that the immune response from the DNA
plasmid was primarily a consequence of transcription by the
eukaryotic host rather than the bacterial vector [26,27].
To directly evaluate the impact of prokaryotic expression on the
immune response induced by DNA vaccines delivered by
Salmonella, a series of genetic manipulations were performed to
eliminate promoter expression in S. typhimurium, while maintaining
activity of the CMV promoter in mammalian cells. Removal of the
primary bacterial promoters, P1 and P2, was insufficient to
eliminate prokaryotic transcription, presumably due to the
presence of additional bacterial promoters. Although small
deletions within the CMV promoter do not affect promoter
activity, large deletions may [28]. Therefore, the trpA bacterial
transcription terminator was inserted at the junction between the
CMV promoter and the C-fragment gene, thereby abrogating the
activity of any bacterial promoters situated within the CMV
promoter. The inclusion of the terminator resulted in a significant
reduction in protein expression from pcDNA3/Cfrag-P1/2-T in
the lysates of S. typhimurium BRD509. Furthermore, there was no
significant difference in anti-TT antibody titres following intra-
muscular injection of pcDNA3/Cfrag-P1/2-T and pcDNA3/
Cfrag-T compared with pcDNA3/Cfrag, indicating that these
DNA vaccines retain comparable function in eukaryotic cells and
are capable of eliciting similar anti-TT antibody responses.
The final step was to evaluate the modified CMV promoter in
the context of an optimised Salmonella/DNA oral delivery platform.
The vaccine cassettes were transferred into pAT153 which has
previously been shown to be the optimal plasmid vector for oral
delivery by S. typhimurium [16]. Following oral delivery by S.
typhimurium BRD509, the only construct capable of inducing a
significant anti-TT antibody response was pAT153/Cfrag, which
contains the unmodified CMV promoter. Compared with the
negative control no significant anti-TT responses were recorded
for mice immunised with pAT153/Cfrag-P1/2-T or pAT153/
Cfrag-T. These findings suggest that successful oral delivery of C-
fragment DNA vaccines by S. typhimurium may be partially
dependant on prokaryotic expression of the antigen and co-
delivery of this protein by Salmonella.
DNA vaccines, processed through the MHC I pathway,
generate a cell-mediated biased immune response. In contrast,
protein vaccines are processed through the MHC II pathway and
produce an antibody biased immune response. As Salmonella
delivered DNA vaccines have a DNA and protein component, it is
plausible that both MHC I and II processing will be employed
which may enhance vaccine immunogenicity. Further work is
required to elucidate and understand the mechanisms of
prokaryotic and eukaryotic antigen processing and presentation
following DNA delivery by Salmonella. By altering the ratio of
MHC I and II processing, vaccine strategies could be designed to
modulate the immune response generated by a vaccine, thereby
more effectively targeting a specific pathogen.
The data presented in this study suggest bacterial antigen
expression may be an important component of inducing an
immune response to a DNA vaccine orally delivered by S.
typhimurium. Additional studies are required to determine the extent
to which these findings can be extrapolated to other bacterial
species, target antigens, doses and routes of immunisation. This
will enable accurate characterisation of the vaccine for commercial
licensing and further optimisation by modification of the ratio of
eukaryotic and prokaryotic expression to improve vaccine
immunogenicity. Additionally, bacterial gene expression from
DNA vaccine constructs raises important safety implications when
handling the modified bacteria, particularly if it contains virulence
or toxin genes. The findings of our study have important
implications for the development, optimisation and commerciali-
sation of the Salmonella/DNA vaccine platform.
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